Storia in 2 fonti

BioNTech, Genentech terminate Phase 2 of personalized mRNA cancer vaccine

BioNTech said Friday that it ended a mid-stage trial that was testing autogene cevumeran as an adjuvant monotherapy in certain colorectal cancer patients.

Raccontata da

endpoints.news

benzinga.com

Confronto fonti

2 prospettive sulla stessa storia

AI · summaries

endpoints.newsStai leggendo4 g fa

BioNTech, Genentech terminate Phase 2 of personalized mRNA cancer vaccine

BioNTech said Friday that it ended a mid-stage trial that was testing autogene cevumeran as an adjuvant monotherapy in certain colorectal cancer patients.

originale

benzinga.com4 g fa

BioNTech Stock Dips After BNT122-01 Trial Termination - BioNTech (NASDAQ:BNTX)

BioNTech shares are dropping Friday after the company decided to end its Phase 2 trial of autogene cevumeran in resected colorectal cancer.

Leggi questa versione → originale

Timeline cronologica

venerdì 28 agosto 2026·endpoints.news
BioNTech, Genentech terminate Phase 2 of personalized mRNA cancer vaccine
BioNTech said Friday that it ended a mid-stage trial that was testing autogene cevumeran as an adjuvant monotherapy in certain colorectal cancer patients.
venerdì 28 agosto 2026·benzinga.com
BioNTech Stock Dips After BNT122-01 Trial Termination - BioNTech (NASDAQ:BNTX)
BioNTech shares are dropping Friday after the company decided to end its Phase 2 trial of autogene cevumeran in resected colorectal cancer.